The purpose of this study is assess the safety and tolerability of AB102 and characterize the pharmacokinetics (PK) profile of AB102 after single and multiple ascending oral dose(s).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
130
Research Site
Groningen, Netherlands
RECRUITINGNumber of participants experiencing Adverse Events (AEs)
Time frame: Up to 49 days
Maximum observed plasma concentration (Cmax) for SAD and MAD Parts
Time frame: Up to 28 days
Time to attain maximum observed plasma concentration (tmax) for SAD and MAD Parts
Time frame: Up to 28 days
Terminal elimination half-life (t1/2) for SAD Part
Time frame: Up to 28 days
Area under the plasma concentration-time curve from time 0 to last sample (AUClast) for SAD and MAD Parts
Time frame: Up to 28 days
Area under the plasma concentration-time curve from time 0 to 24 hours (AUC0-24h) for SAD Part
Time frame: Up to 28 days
Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) for SAD Part
Time frame: Up to 28 days
Area under the plasma concentration-time curve over a dosing interval (AUC0-tau) for MAD Part
Time frame: Up to 28 days
Accumulation ratio (Racc(Cmax))for MAD Part
Time frame: Up to 28 days
Accumulation ratio(Racc(AUCtau)) for MAD Part
Time frame: Up to 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.